Newswire (Published: Monday, January 11, 2021, Received: Monday, January 11, 2021, 5:43:55 PM CST)

Word Count: 453

2021 JAN 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Daily -- A new study on cancer gene therapy is now available. According to news reporting out of the University of Hawaii Cancer Center by NewsRx editors, research stated, “Prostate cancer, which is a bone metastatic cancer, is the second leading cause of cancer-related death in men. There is no effective treatment for metastatic prostate cancer.”

The news journalists obtained a quote from the research from University of Hawaii Cancer Center: “Regucalcin has been shown to contribute as a suppressor in various types of human cancers. In the present study, furthermore, we investigate an involvement of regucalcin in suppression of prostate cancer. Regucalcin expression was compared in 131 primary tumor tissues and 19 metastatic tumor tissues in prostate cancer patients. Regucalcin expression in the metastatic tumor was found to be reduced as compared with that in primary tumor. The progression-free survival rate was prolonged in patients with a higher regucalcin expression. Translationally, overexpression of regucalcin in bone metastatic human prostate cancer PC-3 and DU-145 cells suppressed colony formation and cell growth in vitro. Mechanistically, overexpressed regucalcin enhanced the levels of p53, Rb, and p21, and decreased the levels of Ras, PI3 kinase, Akt, and mitogen-activated protein kinase, leading to suppression of cell growth. Furthermore, higher regucalcin expression suppressed the levels of nuclear factor-kB p65, b-catenin, and signal transducer and activator of transcription 3, which regulate a transcription activity. Cell growth was promoted by culturing with the calcium agonist Bay K 8644. This effect was blocked by overexpression of regucalcin.”

According to the news reporters, the research concluded: “Notably, overexpressed regucalcin suppressed bone metastatic activity of PC-3 and DU-145 cells when cocultured with preosteoblastic or preosteoclastic cells. Regucalcin may suppress the development of human prostate cancer, suggesting that gene delivery systems in which its expression is forced may be a novel therapeutic strategy.”

For more information on this research see: Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cells. Translational Oncology, 2021,14(1):100955. (Translational Oncology - The publisher for Translational Oncology is Elsevier.

A free version of this journal article is available at

Our news editors report that additional information may be obtained by contacting Masayoshi Yamaguchi, Cancer Biology Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, 701 Ilalo Street, Hawaii, HI 96813, USA. Additional authors for this research include Satoru Osuka, Tomiyasu Murata, Joe W. Ramos.

(Our reports deliver fact-based news of research and discoveries from around the world.)


      Healthcare Facilities
            Cancer Centers


North America
United States


Science and Technology
      Scientific Research
            Medical Research
            Natural Sciences
            Applied Biotechnology
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Gene and Genetic Therapy